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Glaucoma is a leading cause of blindness in the world,
affecting almost 5% of persons 70 years.1 It is a pro-
gressive neurological disease of the retina characterized
by optic nerve head remodeling, loss of optic nerve ax-
ons, and loss of retinal ganglion cells. These effects
cause a slow progressive decline of vision, starting in the
periphery, moving over time toward central vision, and
resulting in complete vision loss. Although family history,
ethnicity, and age increase the chances of glaucoma, the
most significant risk factor is an elevated intraocular pres-
sure (IOP).2 Therapies for glaucoma target increased
IOP, such that by lowering the IOP, it is possible to slow
the progression of glaucoma.
The causes of increased IOP have been a challenge to
understand, especially when the most common form of
primary glaucoma has an open angle with no visible
obstruction of aqueous outflow. The increase in IOP of
primary open-angle glaucoma (POAG) is associated with
an increase in aqueous outflow resistance in the tra-
becular meshwork. Many descriptive observations
have been made of trabecular meshwork cells and
matrix protein deposits, but only a few have compared
healthy with glaucomatous eyes. One of the most im-
portant differences between healthy and glaucoma-
tous eyes is the marked increase of active transforming
growth factor (TGF)-2 in the aqueous humor of eyes
with a high IOP.3
A Role for CTGF in Glaucoma
In this issue of The American Journal of Pathology, Junglas
et al4 present a link between the descriptive changes
induced by TGF-2 and the biophysical and molecular
changes in trabecular meshwork cells that are associ-
ated with generation of a high IOP. They used transgenic
techniques to overexpress the TGF-2–induced connec-
tive tissue growth factor (CTGF) in the eyes of mice. Theeyes of these mice develop a high IOP and retinal gan-
glion cell axon loss, just as in human POAG. They also
demonstrate CTGF-mediated POAG-associated morpho-
logical changes in trabecular meshwork cells. The au-
thors provide one of the few mouse models that can be
used to study the early stages of POAG and demonstrate
a central role for CTGF in regulating aqueous outflow
resistance by trabecular meshwork cells.
The matricellular protein CTGF is usually expressed in
wounded tissues,5 but in the eye it is constitutively ex-
pressed by the trabecular meshwork cells.6 CTGF in-
duces fibronectin, collagen production, and actin stress
fibers. The major regulators of CTGF expression are
TGF- and mechanical stress.7 Although mechanical
stress induction of CTGF is dependent on RhoA/Rho ki-
nase,8 the kinase also interacts with the TGF- signaling
pathway.9 This suggests that, in addition to promoting
RhoA-dependent actin assembly, mechanical stress ac-
tivates a second pathway through the TGF- SMADs,
with the two pathways converging on CTGF. Under
healthy conditions, there is constitutive expression of
CTGF and normal mechanical stress in the trabecular
meshwork, suggesting the existence of a mechanism to
maintain a homeostatic level of CTGF and actin stress
fibers in the cells, which is necessary to generate an
outflow resistance. It also means that this process must
function in a narrow range to produce the right amount of
resistance to generate an IOP that is not pathological.
This possibility is supported by the increase in outflow
when healthy eyes are treated with Rho kinase inhibitors,
which lower the IOP and aqueous outflow resistance
across the trabecular meshwork.10,11
In the article by Junglas et al,4 they approach the
question of CTGF activity in POAG partly by generating
transgenic mouse lines expressing CTGF under the
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AJP June 2012, Vol. 180, No. 6 B1-crystallin (CRYBB1) promoter. In these mice, CTGF
is constitutively expressed by lens cells and released into
the aqueous humor. The transgenic strains that moder-
ately express constitutive amounts of CTGF display pro-
gressive increases in fibronectin deposits around
Schlemm’s canal and in the iris and ciliary body. There is
an increase in -smooth muscle actin fibers in the tra-
becular meshwork and an increase in IOP with associ-
ated loss in optic nerve axons. The ultrastructure of the
trabecular meshwork shows bundles of microfilaments of
-smooth muscle actin under the cell membranes, tra-
becular meshwork cell contraction that would cause in-
creased aqueous outflow resistance, and increased IOP.
This contraction is reversed with Rho kinase inhibitor
treatment, resulting in reduction of IOP in the treated
CTGF-transgenic mice. The transgenic mice with POAG
described at the end of the article by Junglas et al,4
combined with the results of in vitro CTGF treatment of
trabecular meshwork cells and in vivo adenovirus gene
delivery of CTGF into the anterior chamber, support a
central role for CTGF in mediating the increase in aque-
ous resistance across the tubercular meshwork. This can
be further defined at the cellular level as a CTGF-medi-
ated increase in actin stress filaments and integrin-focal
contacts and at the biochemical level of Rho kinase ac-
tivity that mediates the contraction or tone of the tuber-
cular meshwork cells.
Regulation of the TGF-2 Signaling Pathway
The production of TGF-2 in the eye is constitutive and
considered to be from the iris and ciliary body cells12–14;
however, TGF-2 is not released by cells in an active
form.3,15 The process of producing and secreting TGF-
results in the release of latent TGF-, consisting of mature
TGF- noncovalently bound to the TGF- proprotein
called latency-associated peptide (LAP). This small latent
TGF- complex is bound through disulfide links between
the LAP and a second separately produced protein
called the latent TGF-–binding protein to make the large
latent TGF- complex. TGF- activity is blocked when it
is bound to LAP, with or without the latent TGF-–
binding protein. It is this large TGF- complex that is
held in the extracellular matrix that sequesters TGF-
until released by proteases that cleave the latent TGF-–
binding protein. When released, it is still in an inactive form
of TGF- bound to LAP in the small latent TGF- complex.
Therefore, an additional activation step is needed to free the
active form of TGF- to bind its receptors.
TGF- activation can be achieved through matrix met-
alloproteases or tissue plasmin that cleaves the LAP to
release TGF-. This can be facilitated by LAP binding to
the integrin v8. In addition to the enzymatic activation,
there are conformational mechanisms of activating
TGF-. When the latent TGF- complex binds to throm-
bospondin-1 or integrin v6, a change in the structural
conformation of LAP releases active TGF-. However,
integrin-induced activation of TGF-2 is not possible be-
cause the TGF-2 LAP lacks the necessary Arg-Gly-Asp
motif to bind. Therefore, the finding of active TGF-2 inthe aqueous humor means that it must result from in-
creased levels of proteases within the anterior chamber.
In addition to activating the expression of CTGF, TGF- is
a potent mediator of fibrosis and a regulator of the cell
cycle and apoptosis. This is mediated by TGF- recep-
tors activating the intracellular SMAD and DAXX path-
ways.16,17 Because of the wide range of cellular activ-
ities regulated by TGF-, and the fact that almost all
cells have receptors for TGF-, its activation is highly
regulated. Therefore, the heightened level of active
TGF-2 in the aqueous humor of eyes with POAG is
important, with the consequence of mediating cellular
changes throughout the anterior chamber, including
the trabecular meshwork cells.
Future Implications
The ocular CTGF-overexpressing transgenic mice pre-
sented by Junglas et al4 as a model to study POAG
provide the means to test new therapies in reducing IOP.
Although this mouse model of POAG will greatly advance
the understanding of the biochemical, cell biological, and
pathological characteristics of POAG, it is not clear if it is
part of the early stages of glaucoma. The finding that the
CTGF transgenic mice exhibit the same morphological
and pathological characteristics as POAG argues
strongly for a central role of CTGF in trabecular meshwork
cell biological characteristics. However, does this also
raise questions regarding the role of active TGF-2? The
simplest answer is that active TGF-2 initiates an over-
expression of CTGF that leads to the physical changes of
the trabecular meshwork cells, resulting in increased
aqueous outflow resistance and IOP. Then, localized pro-
duction and activation of TGF- by the trabecular mesh-
work cells, along with aqueous humor active TGF-, may
sustain the elevated levels of CTGF and the progressive
changes in the trabecular meshwork. These changes
increase the mechanical stress on the trabecular mesh-
work cells, leading to further production of CTGF and
increased IOP. In this way, it is a self-sustaining cycle of
ever-worsening pathological characteristics and one that
can be relieved through Rho kinase inhibitors.
In the transgenic mouse model, a Rho kinase inhibitor
is effective in transiently relaxing the trabecular mesh-
work cells and lowering the IOP in the presence of sus-
tained elevated levels of CTGF. If it is a TGF-–mediated
cycle, then TGF- antagonists should be tested.18 It
would be interesting to know whether there is an increase
in TGF- expression and activation in the trabecular
meshwork of the CTGF-overexpressing mouse eyes.
Also, could antagonists of TGF- signaling neutralize
CTGF production?19 Positive answers would suggest that
the process of trabecular meshwork changes leading to
POAG is mediated by a self-sustaining cycle of patho-
logical expression of active TGF-, CTGF, and Rho ki-
nase activity. This further suggests that, before the dis-
ease progresses with extracellular plaques of fibrillar
material and neurological damage, there may be a sim-
ple growth factor loop by which therapeutic intervention
is the most effective. In this scenario, the progressive
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most benefit. However, this still leaves the following ques-
tion: What is the initiating event that would induce a
pathogenic state in the trabecular meshwork cells lead-
ing to POAG?
The expression of CTGF in trabecular meshwork cells6
and TGF-2 in aqueous humor12–14 is constitutive with
CTGF at a low level of expression and with latent TGF-2.
In glaucomatous eyes, there are elevated levels of acti-
vated TGF-2.3 Therefore, under healthy ocular condi-
tions, there is a sustained level of CTGF that is likely
induced by a steady-state rate of TGF-2 activation in the
trabecular meshwork to maintain a healthy level of aque-
ous outflow resistance. This means that there should be a
healthy homeostatic set point for TGF-2 activation and
CTGF expression. Therefore, POAG may be the result of
an initiated process in eyes that have a higher homeo-
static set point for TGF-2 activation. This could be the
result of trauma or genetic predisposition. It may also be
something that happens often within the eye. The differ-
ence between pathological characteristics and maintain-
ing health is how the trabecular meshwork cells respond
and how retinal ganglion cells survive under a high IOP.
There are several prevalent gene mutations associated
with POAG, but most are carried by 20% of patients
with POAG. These mutations are in genes for a limited set
of proteins that modulate mitochondrial function, protein
transport, neurite outgrowth, and neuroprotection.20
Junglas et al4 note that only transgenic mice with mod-
erate constitutive expression of CTGF express the path-
ological characteristics of POAG. Others have shown that
overexpression of active TGF-1 or TGF-2 in the eye by
adenoviral gene delivery into the anterior chamber
causes fibrosis and closing of the angle, which are not
characteristics of POAG.3 Therefore, POAG is not caused
by extremes in active TGF- nor in CTGF production but
rather by elevated levels that could well be the result of
subtle shifts in activation and production. If not corrected,
there would be induction of a progressive change in the
trabecular meshwork leading to a high IOP and retinal
ganglion cell death. Therefore, the potential exists that
the initiating events of POAG are low levels of abnormal
TGF- activation that induce pathways that include in-
creased CTGF production. Because the animal model is
based on genetic overexpression of CTGF and not de-
pendent on TGF-2 induction, the possibility still exists
that, in POAG, factors other than TGF-2 could be in-
volved in the up-regulation of CTGF in the trabecular
meshwork cells.
Concluding Remarks
Although not all animal models of disease can replicate
all aspects of a human disease, the more models that are
generated, the more insight into different stages of dis-
ease can be achieved. In some cases, this may lead to
rejecting hypotheses regarding disease causation or
may simply not answer such questions. Junglas et al4
have generated a mouse model and provided ample
experimental results to support calling it a mouse modelof POAG. In addition, their mouse model could benefit the
study of other types of human glaucoma associated with
up-regulation of CTGF, such as pseudoexfoliation glau-
coma.21,22 They present detailed descriptions of the mor-
phological and pathological changes expected in a
mouse model of POAG. They demonstrate the role of
CTGF in mediating the changes in trabecular meshwork
cells that increase aqueous outflow resistance in POAG.
Finally, this argues for an important role of TGF-–medi-
ated pathways in the pathological features of glaucoma.3
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